|
Jul 27
|
Cosmo Pharmaceuticals First Half 2025 Earnings: €0.13 loss per share (vs €4.42 profit in 1H 2024)
|
|
Jul 23
|
Cosmo Delivers Strong Performance in H1 2025, Raises Full-Year EBITDA Guidance and Accelerates Recurring Revenue Growth Across AI and Dermatology
|
|
Jul 1
|
Cosmo Unveils Bold 2030 Vision and Strategy; Launches AI-Driven Growth Phase at Investor Day 2025
|
|
Jun 30
|
Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
|
|
Jun 25
|
Cosmo Announces Sale of "Digital Trust" in Strategic Portfolio Streamlining Move
|
|
May 5
|
Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025
|
|
Mar 7
|
Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ...
|
|
Mar 6
|
Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 2025
|
|
Feb 12
|
Cosmo to Host Investor Day on April 9, 2025
|
|
Feb 11
|
Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio
|
|
Feb 10
|
Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne
|